Top Markets
Coin of the day
Liminal BioSciences Inc. Liminal BioSciences Inc.

Liminal BioSciences Inc.

LMNL
Rangering i aksjer #38949
Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm,... Liminal BioSciences Inc. operates as a clinical-stage biopharmaceutical firm, primarily engaged in creating innovative small molecule drug therapies. The company concentrates on addressing inflammatory, fibrotic, and metabolic diseases, with its operations spanning Canada and the United Kingdom. Its flagship drug candidate, fezagepras (identified as PBI-4050), has successfully advanced through Phase I clinical trials. This agent, along with its related derivatives, is undergoing investigation for potential application in treating idiopathic fibrosis affecting the lungs, liver, heart, or skin, as well as various respiratory conditions. Furthermore, Liminal is advancing antagonist programs, including G-protein coupled receptor 84 (GPR84) and Oxo-eicosanoid receptor 1 (OXER1), both of which are currently in preclinical development. Formerly known as Prometic Life Sciences Inc., the company adopted the name Liminal BioSciences Inc. in October 2019. Established in 1994, its corporate headquarters are located in Laval, Canada.
Aksjekurs
$8.50
Sist synkronisert: 2023-09-26
Markedsverdi
$719.10K
Endring (1 dag)
0.00%
Endring (1 år)
0.00%
Land
CA
Handel Liminal BioSciences Inc. (LMNL)

Kategori

Aksjeprishistorikk for Liminal BioSciences Inc. (LMNL)
Høyeste sluttskurs: $8.45 den 2023-09-01

Laveste sluttskurs: $1.69K den 2009-12-01
Aksjeprishistorikk for Liminal BioSciences Inc. fra 2009 til 2026
Årlig aksjeprisytelse
År Ytelse
2023 112.62%
2022 -61.46%
2021 -76.57%
2020 -35.75%
2019 -97.45%
2018 -73.89%
2017 -28.49%
2016 -38.09%
2015 36.88%
2014 102.93%
2013 334.33%
2012 40.83%
2011 23.59%
2010 -34.41%
2009 0.00%
Aksjepris for lignende selskaper eller konkurrenter
Selskap Aksjepris Endring 1år% Land
$507.52 30.03%
US
$847.62 29.92%
NL
$731.69 7.13%
CH
$1.07K -6.40%
KR
$251.82 11.25%
BE